Kognitivni upad in demenca pri Parkinsonovi bolezni
DOI:
https://doi.org/10.6016/ZdravVestn.3003Ključne besede:
Parkinsonova bolezen, kognitivni upad, nevrodegenerativne bolezni, spoznavne sposobnostiPovzetek
Parkinsonova bolezen (PB) je nevrodegenerativna bolezen možganov, ki se kaže z motoričnimi in nemotoričnimi znaki. Med motorične znake prištevamo tremor, rigidnost in bradikinezijo, med nemotoričnimi pa je najpogostejši kognitivni upad.
Rezultati longitudinalnih raziskav kažejo, da pri 80 % bolnikov kognitivni upad napreduje do demence (PBD). Vpliv PBD na življenje je velik. Če kognitivni upad prepoznamo dovolj zgodaj, lahko simptome PBD olajšamo in s tem izboljšamo kakovost posameznikovega življenja.
V preglednem članku se bomo dotaknili najpogostejših vzrokov za nastanek kognitivnega upada, vpliva dednosti in prikazali značilno klinično sliko. Za prepoznavo kognitivnega upada uporabljamo kognitivne teste, npr. Montrealsko lestvico ocenjevanja spoznavnih sposobnosti (MoCA), Baterijo testov frontalnih funkcij (FAB), Kratek poskus spoznavnih sposobnosti (KPSS) in test Testiraj svoj spomin (TSS). Na koncu članka bomo prikazali možnosti simptomatskega zdravljenja z zdravili, ki jih imamo na voljo, ter z zdravili in postopki, ki so še v fazi razvoja.
Prenosi
Literatura
1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-4.
DOI: 10.1136/jnnp.55.3.181
PMID: 1564476
2. Safarpour D, Willis AW. Clinical Epidemiology, Evaluation, and Management of Dementia in Parkinson Disease. Am J Alzheimers Dis Other Demen. 2016;31(7):585-94.
DOI: 10.1177/1533317516653823
PMID: 27295974
3. Garcia-Ptacek S, Kramberger MG. Parkinson Disease and Dementia. J Geriatr Psychiatry Neurol. 2016;29(5):261-70.
DOI: 10.1177/0891988716654985
PMID: 27502301
4. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology. 2016;27(6):730-6.
DOI: 10.1212/wnl.56.6.730
PMID: 11274306
5. Gomperts SN. Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia. Continuum (Minneap Minn). 2016;22:435-63.
DOI: 10.1212/CON.0000000000000309
PMID: 27042903
6. Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies. F1000 Res. 2017;6:1604.
DOI: 10.12688/f1000research.11725.1
PMID: 28928962
7. Aarsland D, Ballard CG, Halliday G. Are Parkinson’s disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol. 2004;17(3):137-45.
DOI: 10.1177/0891988704267470
PMID: 15312277
8. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al.; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-72.
DOI: 10.1212/01.wnl.0000187889.17253.b1
PMID: 16237129
9. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689-707.
DOI: 10.1002/mds.21507
PMID: 17542011
10. Okazaki H, Lipkin LE, Aronson SM; OKAZAKI H. LIPKIN LE, ARONSON SM. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol. 1961;20(2):237-44.
DOI: 10.1097/00005072-196104000-00007
11. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-40.
DOI: 10.1038/42166
PMID: 9278044
12. McKeith IG, Burn D. Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. Neurol Clin. 2000;18(4):865-902.
DOI: 10.1016/S0733-8619(05)70230-9
PMID: 11072265
13. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010;289(1-2):18-22.
DOI: 10.1016/j.jns.2009.08.034
PMID: 19733364
14. Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133(Pt 6):1755-62.
DOI: 10.1093/brain/awq059
PMID: 20371510
15. Lawson RA, Yarnall AJ, Duncan GW, Khoo TK, Breen DP, Barker RA, et al. Severity of mild cognitive impairment in early Parkinson’s disease contributes to poorer quality of life. Parkinsonism Relat Disord. 2014;20(10):1071-5.
DOI: 10.1016/j.parkreldis.2014.07.004
PMID: 25074728
16. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-90.
DOI: 10.1002/mds.25945
PMID: 24976103
17. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology. 2000;54(8):1596-602.
DOI: 10.1212/WNL.54.8.1596
PMID: 10762499
18. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387-92.
DOI: 10.1001/archneur.60.3.387
PMID: 12633150
19. Leroi I, McDonald K, Pantula H, Harbishettar V. Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol. 2012;25(4):208-14.
DOI: 10.1177/0891988712464823
PMID: 23172765
20. Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, et al. Longitudinal study of normal cognition in Parkinson disease. Neurology. 2015;85(15):1276-82.
DOI: 10.1212/WNL.0000000000002001
PMID: 26362285
21. Willis AW, Schootman M, Kung N, Evanoff BA, Perlmutter JS, Racette BA. Predictors of survival in patients with Parkinson disease. Arch Neurol. 2012;69(5):601-7.
DOI: 10.1001/archneurol.2011.2370
PMID: 22213411
22. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837-44.
DOI: 10.1002/mds.21956
PMID: 18307261
23. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008;70(13):1017-22.
DOI: 10.1212/01.wnl.0000306632.43729.24
PMID: 18362281
24. Reid WG, Hely MA, Morris JG, Loy C, Halliday GM. Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry. 2011;82(9):1033-7.
DOI: 10.1136/jnnp.2010.232678
PMID: 21335570
25. Posada I, Benito-León J, Louis ED, Trincado R, Villarejo A, Medrano MJ, et al. Mortality from Parkinson’s disease: A population-based prospective study. 2011;26(14):2522-9.
DOI: 10.1002/mds.23921
PMID: 221915906
26. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255-63.
DOI: 10.1002/mds.20527
PMID: 16041803
27. Oh YS, Kim JS, Park IS, Shim YS, Song IU, Park JW, et al. Prevalence and treatment pattern of Parkinson’s disease dementia in Korea. Geriatr Gerontol Int. 2016;16(2):230-6.
DOI: 10.1111/ggi.12457
PMID: 25656841
28. Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease. J Neurol. 2010;257(7):1073-82.
DOI: 10.1007/s00415-010-5465-z
PMID: 20140443
29. Wang Q, Zhang Z, Li L, Wen H, Xu Q. Assessment of cognitive impairment in patients with Parkinson’s disease: prevalence and risk factors. Clin Interv Aging. 2014;9:275-81.
PMID: 24550669
30. Romo-Gutiérrez D, Yescas P, López-López M, Boll MC. Genetic factors associated with dementia in Parkinson’s disease (PD). Gac Med Mex. 2015;151(1):110-8.
PMID: 25739491
31. Willis A, Evanoff BA, Lian M, Criswell SR, Racette BA. Wright Geographic and Ethnic Variation in Parkinson Disease: study of Beneficiaries. Neuroepidemiology. 2010;34(3):143-51.
DOI: 10.1159/000275491
PMID: 20090375
32. Anang JB, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M, et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology. 2014;83(14):1253-60.
DOI: 10.1212/WNL.0000000000000842
PMID: 25171928
33. Gratwicke J, Jahanshahi M, Foltynie T. Parkinson’s disease dementia: a neural networks perspective. Brain. 2015;138(Pt 6):1454-76.
DOI: 10.1093/brain/awv104
PMID: 25888551
34. Inzelberg R, Schecthman E, Paleacu D, Zach L, Bonwitt R, Carasso RL, et al. Onset and progression of disease in familial and sporadic Parkinson’s disease. Am J Med Genet A. 2004;124A(3):255-8.
DOI: 10.1002/ajmg.a.20405
PMID: 14708097
35. Goker-Alpan O, Masdeu JC, Kohn PD, Ianni A, Lopez G, Groden C, et al. The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain. 2012;135(Pt 8):2440-8.
DOI: 10.1093/brain/aws174
PMID: 22843412
36. Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70(6):727-35.
DOI: 10.1001/jamaneurol.2013.1925
PMID: 23588557
37. Gan-Or Z, Mirelman A, Postuma RB, Arnulf I, Bar-Shira A, Dauvilliers Y, et al. GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. Ann Clin Transl Neurol. 2015;2(9):941-5.
DOI: 10.1002/acn3.228
PMID: 26401515
38. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41(12):937-40.
DOI: 10.1136/jmg.2004.024455
PMID: 15591280
39. Kim WS, Kågedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014;6(5):73.
DOI: 10.1186/s13195-014-0073-2
PMID: 25580161
40. Ibáñez P, Lesage S, Janin S, Lohmann E, Durif F, Destée A, et al.; French Parkinson’s Disease Genetics Study Group. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism: frequency, phenotype, and mechanisms. Arch Neurol. 2009;66(1):102-8.
DOI: 10.1001/archneurol.2008.555
PMID: 19139307
41. Nombela C, Rowe JB, Winder-Rhodes SE. Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain. 2014;137(Pt 10):2743-58.
DOI: 10.1093/brain/awu201
PMID: 25080285
42. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, et al. Tau and α-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol. 2007;62(2):145-53.
DOI: 10.1002/ana.21192
PMID: 17683088
43. Srivatsal S, Cholerton B, Leverenz JB. Cognitive Profile of LRRK2-related Parkinson’s Disease. Mov Disord Off J Mov Disord Soc. 2015;62(2):145-53.
DOI: 10.1002/ana.21192
PMID: 17683088
44. Pagonabarraga J, Kulisevsky J. Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis. 2012;46(3):590-6.
DOI: 10.1016/j.nbd.2012.03.029
PMID: 22484304
45. Sohlberg MK, Mateer CA. Improving Attention and Managing Attentional Problems. Ann N Y Acad Sci. 2001;931(1):359-75.
DOI: 10.1111/j.1749-6632.2001.tb05790.x
PMID: 22484304
46. Bronnick K, Ehrt U, Emre M. Attentional deficits affect activities of daily living in dementia associated with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77(10):1136-42.
DOI: 10.1136/jnnp.2006.093146
PMID: 16801351
47. Costa A, Monaco M, Zabberoni S, Chao L. Free and Cued Recall Memory in Parkinson’s Disease Associated with Amnestic Mild Cognitive Impairment. PLoS ONE. 2014;9(1):e86233.
DOI: 10.1371/journal.pone.0086233
PMID: 24465977
48. Takemoto M, Sato K, Hatanaka N, Yamashita T, Ohta Y, Hishikawa N, et al. Different Clinical and Neuroimaging Characteristics in Early Stage Parkinson’s Disease with Dementia and Dementia with Lewy Bodies. J Alzheimers Dis. 2016;52(1):205-11.
DOI: 10.3233/JAD-150952
PMID: 27060948
49. Chiu P, Tsai C, Chen P, Chen W, Lai T. Neuropsychiatric Symptoms in Parkinson’s Disease Dementia Are More Similar to Alzheimer’s Disease than Dementia with Lewy Bodies: A Case-Control Study. PLoS One. 2016;11(4):e0153989.
DOI: 10.1371/journal.pone.0153989
PMID: 27101140
50. Goetz C, Fan W, Leurgans S, Bernard B, Stebbins G.. The Malignant Course of “Benign Hallucinations” in Parkinson Disease. Arch Neurol. 2006;63(5):713-6.
DOI: 10.1001/archneur.63.5.713
PMID: 16682540
51. Zadikoff C, Fox S, Tang-Wai D, Thomsen T, de Bie R., et al. A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord. 2008;23(2):297-9.
DOI: 10.1002/mds.21837
PMID: 18044697
52. Biundo R, Weis L, Bostantjopoulou S.. MMSE and MoCA in Parkinson’s disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. J Neural Transm (Vienna). 2016;123(4):431-8.
DOI: 10.1007/s00702-016-1517-6
PMID: 26852137
53. Djukic M, Wedekind D, Franz A, Gremke M, Nau R. Frequency of dementia syndromes with a potentially treatable cause in geriatric in-patients: analysis of a 1-year interval. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):429-38.
DOI: 10.1007/s00406-015-0583-3
PMID: 25716929
54. Mak E, Su L, Williams GB, Brien JT. Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res Ther. 2014;6(2):18.
DOI: 10.1186/alzrt248
PMID: 25031634
55. Melzer T, Watts R, MacAskill M, Pitcher T, Livingston L., et al. Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83(2):188-94.
DOI: 10.1136/jnnp-2011-300828
PMID: 21890574
56. Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84(11):1104-13.
DOI: 10.1212/WNL.0000000000001364
PMID: 25681454
57. Wang H, Yu J, Tang S, Jiang T, Tan C., et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135-43.
DOI: 10.1136/jnnp-2014-307659
PMID: 24828899
58. Emre M, Aarsland D, Albanese A, Byrne E, Deuschl G., et al. Rivastigmine for Dementia Associated with Parkinson’s Disease. N Engl J Med. 2004;351(24):2509-18.
DOI: 10.1056/NEJMoa041470
PMID: 15590953
59. Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, et al. Targeting impulsivity in Parkinson’s disease using atomoxetine. Brain. 2014;137(Pt 7):1986-97.
DOI: 10.1093/brain/awu117
PMID: 24893708
60. Rakuša M. Demenca pri Parkinsonovi bolezni. In: Menih M. Obravnava bolnika s Parkinsonovo boleznijo. In: Maribor: Univerzitetni Klinični Center Maribor; 2018. pp. 10-13.
61. Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633-7.
DOI: 10.4088/JCP.v66n0514
PMID: 15889951
62. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K., et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-40.
DOI: 10.1016/S0140-6736(13)62106-6
PMID: 24183563
63. Hindle J, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson’s disease: A systematic review. Mov Disord. 2013;28(8):1034-49.
DOI: 10.1002/mds.25377
PMID: 23426759
64. Srovnalova H, Marecek R, Rektorova I. The role of the inferior frontal gyri in cognitive processing of patients with Parkinson’s disease: a pilot rTMS study. Mov Disord. 2011;26(8):1545-8.
DOI: 10.1002/mds.23663
PMID: 21480374
65. Paris AP, Saleta H, Maraver M, Silvestre E, Freixa MG, Torrellas CP, et al. Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease. Mov Disord. 2011;26(7):1251-8.
DOI: 10.1002/mds.23688
PMID: 21442659
66. Hughes TF, Becker JT, Lee C, Chang C, Ganguli M. W. Independent and combined effects of cognitive and physical activity on incident MCI. Alzheimers Dement. 2015;11(11):1377-84.
DOI: 10.1016/j.jalz.2014.11.007
PMID: 25684687
67. McConnell GC, So RQ, Hilliard JD, Lopomo P, Grill WM. Effective deep brain stimulation suppresses low-frequency network oscillations in the basal ganglia by regularizing neural firing patterns. J Neurosci. 2012;32(45):15657-68.
DOI: 10.1523/JNEUROSCI.2824-12.2012
PMID: 23136407
68. van Hartevelt TJ, Cabral J, Deco G, Møller A, Green AL, Aziz TZ, et al. Neural Plasticity in Human Brain Connectivity: The Effects of Long Term Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson’s Disease. PLoS One. 2014. ;9(1)p. e86496.
DOI: 10.1371/journal.pone.0086496
PMID: 24466120
69. Barnikol TT, Pawelczyk NB, Barnikol UB, Kuhn J, Lenartz D, Sturm V, et al. Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome. Mov Disord. 2010;25(10):1519-20.
DOI: 10.1002/mds.23141
PMID: 20629167
70. ANAVEX2-73 Study in Parkinson's Disease Dementia. Available from: https://clinicaltrials.gov/ct2/show/NCT03774459.
Prenosi
Objavljeno
Številka
Rubrika
Licenca
Avtor na prispevku, ki ga bo pripravil za Zdravniški vestnik, po pogodbi nanj prenaša vse materialne avtorske pravice, kakor izhajajo iz 22. člena Zakona o avtorski in sorodnih pravicah, in sicer pravico reproduciranja, pravico javnega izvajanja, pravico javnega prenašanja, pravico javnega predvajanja s fonogrami in videogrami, pravico javnega prikazovanja, pravico radiodifuznega oddajanja, pravico radiodifuzne retransmisije, pravico sekundarnega radiodifuznega oddajanja, pravico dajanja na voljo javnosti, pravico predelave, pravico avdiovizualne priredbe, pravico distribuiranja ter pravico dajanja v najem in vse druge pravice avtorja v skladu z ZASP.
Avtorjev prenos pravic po pogodbi je neizključen, velja za neomejeno število izdaj, za ves čas trajanja materialnih avtorskih pravic ter je prostorsko neomejen.
Avtor sme avtorsko delo tudi sam izkoriščati ali avtorske pravice prenašati na tretje osebe, vendar oboje šele po preteku 3 mesecev od prve objave dela v reviji Zdravniški vestnik.
Avtor Zdravniškemu vestniku izrecno dovoli, da lahko pravice, pridobljene v skladu s pogodbo prenaša naprej na tretje osebe brez omejitev.
Avtor se strinja, da Zdravniški vestnik prispevek objavi pod pogoji licence Creative Commons BY-NC 4.0 (navedba avtorstva-nekomercialno) ali primerljive licence.
